Skip to Content

Patrick Hwu, M.D.

Present Title & Affiliation

Primary Appointment

Department Chair, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement


Dr. Patrick Hwu is considered one of the leading tumor immunologists in the country, and a primary force in the development of novel vaccine and adoptive T-cell therapies. His laboratory and clinical work have led to insights and advances in the understanding of the interactions between tumors and the immune system, and the development of cellular immunotherapies. He was recruited to be the first Chairman of the Department of Melanoma Medical Oncology in 2003. Since that time, he has also served as Associate Director of the Center for Cancer Immunology Research and is the current Chair of MD Anderson Cancer Center’s Promotion and Tenure Committee. His laboratory is significantly funded by the National Cancer Institutes. He is the principal investigator on three RO1 translational immunotherapy grants, as well as a P01 comprehensive program grant that is investigating the use of plasmacytoid dendritic cells to enhance immunotherapy. Dr. Hwu is a member of the editorial board of the Journal of Immunotherapy. He is a frequently requested national and international lecturer. He has published more than 90 peer-reviewed articles.  Dr. Hwu is the recipient of numerous awards such as the George and Barbara Bush Endowment for Innovative Cancer Research in 2004, the Robert R. Herring Professorship in Clinical Research 2004 – 2007, the Moshe Talpaz Endowed Chair in Immunology from 2007 to present, and the Division of Cancer Medicine Hematology/Oncology Fellowship Program Mentor of the Year for FY2009, just to name a few.

Research Interests


Cancer Vaccines, Tumor Immunotherapy and Cancer Immunology


Significant advances in our understanding of the immune response against cancer have allowed us to design novel immune therapies for patients. My laboratory is focused on the translation of basic immunologic concepts from the laboratory to the clinic. We have found that some patients with metastatic cancer can be successfully treated with infusions of tumor-reactive T -cells. We are currently investigating methods to improve these therapies, by studying T-cell proliferation, survival, and trafficking using both murine models and human T -cells.

Office Address

The University of Texas MD Anderson Cancer Center, Administrative Office
Department of Melanoma Medical Oncology
1515 Holcombe Blvd
Unit Number: 430
Houston, TX 77030
Room Number: FC11.3028
Phone: 713-563-1728
Fax: 713-745-1046
The University of Texas MD Anderson Cancer Center, Research Office
Melanoma Medical Oncology - Research
7455 Fannin Street
Unit Number: 904
Houston, TX 77054
Room Number: 1SCR2.3023

Education & Training

Degree-Granting Education

1987 The Medical College of Pennsylvania (MCP), Philadelphia, PA, MD, Magna Cum Laude, Medicine
1983 Lehigh University, Bethlehem, PA, BA, Summa Cum Laude, Premedical Science

Postgraduate Training

1989-1993 Fellowship, Medical Oncology and Immunology, National Cancer Institutes, Bethesda, MD
1987-1989 House Officer, Internal Medicine, The Johns Hopkins Hospital, Baltimore, MD

Board Certifications

10/2008 Medical Oncology, 1st issued 12/1993, renewed

Selected Publications

Peer-Reviewed Original Research Articles

1. Sim GC, Chacon J, Haymaker C, Ritthipichai K, Singh M, Hwu P, Radvanyi L. Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Rationale and Issues for Further Clinical Development. BioDrugs. e-Pub 6/3/2014. PMID: 24890028.
2. Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Pathways and therapeutic targets in melanoma. Oncotarget 5(7):1701-52, 4/15/2014. PMCID: PMC4039128.
3. Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R, Hwu WJ, Bedikian AY, Davies MA, Woodman SE, Hwu P. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma. Melanoma Res. e-Pub 4/16/2014. PMID: 24743052.
4. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2(4):361-70, 4/2014. e-Pub 1/10/2014. PMCID: PMC4000553.
5. Sim GC, Martin-Orozco N, Jin L, Yang Y, Wu S, Washington E, Sanders D, Lacey C, Wang Y, Vence L, Hwu P, Radvanyi L. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest. e-Pub 12/2/2013. PMCID: PMC3871216.
6. Bucheit AD, Syklawer E, Jakob JA, Bassett RL, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, Davies MA. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 119(21):3821-9, 11/1/2013. e-Pub 8/6/2013. PMID: 23922205.
7. Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol 24(8):2158-65, 8/2013. PMID: 23576709.
8. Dietz WM, Skinner NE, Hamilton SE, Jund MD, Heitfeld SM, Litterman AJ, Hwu P, Chen ZY, Salazar AM, Ohlfest JR, Blazar BR, Pennell CA, Osborn MJ. Minicircle DNA is Superior to Plasmid DNA in Eliciting Antigen-specific CD8(+) T-cell Responses. Mol Ther 21(8):1526-35, 8/2013. e-Pub 5/21/2013. PMCID: PMC3734653.
9. Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P. Chemical Castration of Melanoma Patients Does Not Increase the Frequency of Tumor-specific CD4 and CD8 T Cells After Peptide Vaccination. J Immunother 36(4):276-86, 5/2013. PMID: 23603862.
10. Chakravarti N, Peddareddigari VG, Warneke CL, Johnson MM, Overwijk WW, Hwu P, Prieto VG. Differential expression of the G-protein-coupled formyl peptide receptor in melanoma associates with aggressive phenotype. Am J Dermatopathol 35(2):184-90, 4/2013. e-Pub 11/2012. PMID: 23147350.
11. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, Sowell RT, Schluns KS, Davis RE, Hwu P, Overwijk WW. Persistent antigen at vaccination sites induces tumor-specific CD8 T cell sequestration, dysfunction and deletion. Nat Med 19(4):465-72, 4/2013. e-Pub 3/3/2013. PMCID: PMC3618499.
12. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19(5):1225-31, 3/1/2013. e-Pub 1/10/2013. PMCID: PMC3752683.
13. Peng W, Lizée G, Hwu P. Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. Oncoimmunology 2(2):e22691, 2/1/2013. PMCID: PMC3601154.
14. Khalili JS, Hwu P, Lizée G. Forging a link between oncogenic signaling and immunosuppression in melanoma. Oncoimmunology 2(2):e22745, 2/1/2013. PMCID: PMC3601157.
15. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, Demarini DJ, Le NT, Patel K, Lewis KD. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31(4):482-9, 2/1/2013. e-Pub 12/17/2012. PMID: 23248257.
16. Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P. Advances in the development of cancer immunotherapies. Trends Immunol 34(2):90-8, 2/2013. e-Pub 9/30/2012. PMCID: PMC3565019.
17. Yang Y, Lizée G, Hwu P. Strong emerging rationale for combining oncogene-targeted agents with immunotherapy. Oncoimmunology 2(2):e22730, 2/2013. PMID: 23525189.
18. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 19(2):393-403, 1/15/2013. e-Pub 11/30/2012. PMID: 23204132.
19. Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One 8(4):e60031, 2013. PMCID: PMC3613355.
20. Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target Cancer. Annu Rev Med 64:71-90, 2013. e-Pub 10/2012. PMID: 23092383.
21. Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ. Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol 189(11):5476-84, 12/1/2012. e-Pub 10/26/2012. PMCID: PMC3504175.
22. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758-70, 12/15/2012. e-Pub 10/2/2012. PMCID: PMC3525747.
23. Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P. Anti-tumor T cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 120(23):4533-43, 11/29/2012. e-Pub 8/30/2012. PMCID: PMC3512233.
24. Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, Davies MA, Hwu P, Atkins MB, Sullivan RJ. Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. J Immunother 35(9):711-5, 11/2012. PMID: 23090080.
25. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizée G. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 18(1):5329-40, 10/1/2012. e-Pub 7/31/2012. PMCID: PMC3463754.
26. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, Hwu P. PD-1 Blockade enhances T-cell migration to tumors by elevating IFN-γ inducible Chemokines. Cancer Res 72(20):5209-18, 10/15/2012. e-Pub 8/20/2012. PMCID: PMC3476734.
27. Noor R, Bedikian AY, Mahoney S, Bassett R, Kim K, Papadopoulos N, Hwu WJ, Hwu P, Homsi J. Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy. Support Care Cancer 20(10):2583-8, 10/2012. e-Pub 1/25/2012. PMID: 22274951.
28. Zhang M, Maiti S, Bernatchez C, Huls H, Rabinovich B, Champlin RE, Vence LM, Hwu P, Radvanyi L, Cooper LJ. A new approach to simultaneously quantify both TCR α- and β-chain diversity after adoptive immunotherapy. Clin Cancer Res 18(17):4733-42, 9/1/2012. e-Pub 7/3/2012. PMCID: PMC3823368.
29. Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol 39(9):821-5, 9/2012. e-Pub 7/19/2012. PMCID: PMC3881367.
30. Wu RC, Hwu P, Radvanyi LG. New insights on the role of CD8(+)CD57(+) T-cells in cancer. Oncoimmunology 1(6):954-6, 9/2012. PMID: 23162769.
31. Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Ng CS, Wei W, Johnson MM, Wittemer SM, Vardeleon A, Reckeweg A, Colevas AD. A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res 22(4):294-301, 8/2012. e-Pub 6/2012. PMCID: PMC3880198.
32. Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014-23, 8/2012. e-Pub 12/2011. PMID: 2180178.
33. Alvarado G, Noor R, Bassett R, Papadopoulos NE, Kim KB, Hwu WJ, Bedikian A, Patel S, Hwu P, Davies MA. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res 22(4):310-5, 8/2012. e-Pub 5/2012. PMID: 22584956.
34. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med 366(26). e-Pub 6/2012. PMID: 22658128.
35. Wu RC, Liu S, Chacon JA, Wu S, Li Y, Sukhumalchandra P, Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi LG. Detection and Characterization of a Novel Subset of CD8+CD57+ T-cells in Metastatic Melanoma with an Incompletely-Differentiated Phenotype. Clin Cancer Res 18(9):2465-77, 5/1/2012. e-Pub 2/3/2012. PMCID: PMC3343210.
36. Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G, Hwu P. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 18(8):2326-35, 4/15/2012. e-Pub 2/21/2012. PMID: 22355009.
37. Bernatchez C, Radvanyi LG, Hwu P. Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. Semin Oncol 39(2):215-26, 2012 Apr, 4/2012. PMID: 22484193.
38. Liu C, Lewis CM, Lou Y, Xu C, Peng W, Yang Y, Gelbard AH, Lizée G, Zhou D, Overwijk WW, Hwu P. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J Immunother 35(3):276-82, 4/2012. PMCID: PMC3860320.
39. Chung Y, Lee YH, Zhang Y, Martin-Orozco N, Yamazaki T, Zhou D, Kang CY, Hwu P, Kwak LW, Dong C. T cells and T cell tumors efficiently generate antigen-specific cytotoxic T cell immunity when modified with an NKT ligand. Oncoimmunology 1(2):141-51, 3/1/2012. PMCID: PMC3376985.
40. Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 18(2):160-75., Mar-Apr, 3/2012. PMCID: PMC3315690.
41. Davies MA, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng CS, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res 18(4):1120-8, 2/15/2012. e-Pub 1/5/2012. PMCID: PMC3906678.
42. Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, Hwu P, Atkins MB, Davies MA. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 35(1):66-72, 1/2012. PMID: 22130161.
43. Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol 5(1):15, 2012. e-Pub 4/4/2012. PMCID: PMC3350393.
44. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Hakansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Nelief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the Critical Hurdles in Cancer Immunotherapy. J Transl Med 9(1):214, 12/2011. e-Pub 12/2011. PMID: 22168571.
45. Petrelli A, Carvello M, Vergani A, Lee KM, Tezza S, Du M, Kleffel S, Chengwen L, Mfarrej BG, Hwu P, Secchi A, Leonard W, Young D, Markmann JF, Zajac AJ, Fiorina P. IL-21 Is an Antitolerogenic Cytokine of the Late-Phase Alloimmune Response. Diabetes 60(12):3223-34, 12/2011. PMID: 22013017.
46. Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Homsi J, Davies M, McIntyre S, Hwu P. Predictive factors for the Development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol 34(6):603-10, 12/2011. e-Pub 12/2010. PMID: 21150567.
47. Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197(6):W992-W1000, 12/2011. PMID: 2109345.
48. Chang DZ, Ma Y, Ji B, Wang H, Deng D, Liu Y, Abbruzzese JL, Liu YJ, Logsdon CD, Hwu P. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin Cancer Res 17(22):5-23, 11/15/2011. e-Pub 10/5/2011. PMID: 21976550.
49. Chang M, Jin W, Chang JH, Xiao Y, Brittain GC, Yu J, Zhou X, Wang YH, Cheng X, Li P, Rabinovich BA, Hwu P, Sun SC. The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat Immunol 12(10):1002-9, 10/2011. e-Pub 8/28/2011. PMCID: PMC3178748.
50. Patel SP, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P, Prieto VG, Bar-Eli M, Zigler M, Dobroff A, Bronstein Y, Bassett RL, Vardeleon AG, Bedikian AY. A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res 21(4):357-63, 8/2011. PMID: 21738104.
51. Joseph RW, Peddareddigari VR, Liu P, Miller P, Overwijk W, Bekele BN, Ross MI, Lee JS, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim KB, Homsi J, Bedikian AY, Hwu WJ, Hwu P, Radvanyi L. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res 17(14):4882-91, 7/2011. e-Pub 6/2011. PMID: 21632855.
52. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P. Peptide vaccine and IL-2 in patients with advanced Melanoma. New Engl J Med 364(22):2119-27, 6/2011. PMID: 21631324.
53. Li Y, Efferson CL, Ramesh R, Peoples GE, Hwu P, Ioannides CG. A peptidoglycan monomer with the glutamine to serine change and basic peptides bind in silico to TLR-2 (403-455). Cancer Immunol Immunother 60(4):403-455, 4/2011. e-Pub 12/28/2010. PMID: 21188584.
54. Bernatchez C, Zhu K, Li Y, Andersson H, Ionnides C, Fernandez-Vina M, Cano P, Cooper L, Abbruzzese J, Hwu P, Chang DZ, Radvanyi LG. Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. Vaccine 29(16):3021-30, 4/2011. e-Pub 2/2011. PMID: 21320548.
55. Lou Y, Liu C, Lizée G, Peng W, Xu C, Ye Y, Rabinovich BA, Hailemichael Y, Gelbard A, Zhou D, Overwijk WW, Hwu P. Antitumor Activity Mediated by CpG: The Route of Administration is Critical. J Immunother 34(3):279-88, 4/2011. PMID: 21389870.
56. Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 34(3):236-50, 4/2011. PMID: 21389874.
57. Park HJ, Qin H, Cha SC, Sharma R, Chung Y, Schluns KS, Neelapu SS, Overwijk WW, Hwu P, Kwak LW. Induction of TLR4-dependent CD8+ T cell immunity by murine β-defensin2 fusion protein vaccines. Vaccine 29(18):3476-82, 4/2011. e-Pub 3/2011. PMID: 21382485.
58. Alvarado GC, Papadopoulos NE, Hwu WJ, Bedikian AY, Homsi J, Myers JN, Bronstein Y, Bassett RL, Hwu P, Kim KB. Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck. Melanoma Res 21(2):127-30, 4/2011. e-Pub 12/2010. PMID: 21169870.
59. Homsi J, Grimm JC, Hwu P. Immunotherapy of melanoma: an update. Surg Oncol Clin N Am 20(1):145-63, 1/2011. PMID: 21111964.
60. Ahrar J, Gupta S, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P, Bedikian AY. Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma. Cancer Invest 29(1):49-55, 1/2011. PMID: 21166498.
61. Martin-Orozco N, Li Y, Wang Y, Liu S, Hwu P, Liu YJ, Dong C, Radvanyi L. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res 70(23):9581-90, 12/1/2010. e-Pub 11/23/2010. PMCID: PMC3058814.
62. Homsi J, Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Mahoney SL, Hwu P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res 20(6):507-10, 12/2010. PMID: 20881508.
63. Hwu WJ, Knight RD, Patnana M, Bassett R, Papadopoulos NE, Kim KB, Hwu P, Bedikian A. Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. Melanoma Res 20(6):501-6, 12/2010. e-Pub 9/2010. PMID: 20859231.
64. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim KB, Hwu WJ, McIntyre S, Rohlfs M, Homsi J, Hwu P. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? Melanoma Res 21(1). e-Pub 11/22/2010. PMID: 21102360.
65. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y, Overwijk WW, Lizée G, Hwu P. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 16(22):5458-68, 11/15/2010. e-Pub 10/1/2010. PMCID: PMC3476703.
66. Li D, Li Y, Hernandez JA, Patenia R, Kim TK, Khalili J, Dougherty MC, Hanley PJ, Bollard CM, Komanduri KV, Hwu P, Champlin RE, Radvanyi LG, Molldrem JJ, Ma Q. Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs. J Immunother 33(9):975-82, Nov-Dec, 11/2010. PMID: 20948439.
67. Carreńo R, Brown WS, Li D, Hernandez JA, Wang Y, Kim TK, Craft JW, Komanduri KV, Radvanyi LG, Hwu P, Molldrem JJ, Legge GB, McIntyre BW, Ma Q. 2E8 binds to the high-affinity I-domain in a metal ion dependent manner: A second generation monoclonal antibody selectively targeting activated LFA-1. J Biol Chem 285(43):32860-8, 10/22/2010. e-Pub 8/19/2010. PMCID: PMC2963386.
68. Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P. Hepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver: Response, Survival, and Prognostic Factors. Am J Clin Oncol 33(5):474-80, 10/2010. e-Pub 11/2009. PMID: 19935383.
69. Bedikian AY, Silverman JA, Papodopoulos NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsi J, Davies M, Hwu P. Pharmacokinetics and Safety of Marqibo (Vincristine Sulfate Liposomes Injection) in Cancer Patients With Impaired Liver Function. J Clin Pharmacol 51(8). e-Pub 10/2010. PMID: 20978276.
70. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A. Prognostic factors for survival in melanoma patients with brain metastases. Cancer - Am Cancer Soc 117(8). e-Pub 10/2010. PMID: 20960525.
71. Chemaly RF, Sharma PS, Youssef S, Gerber D, Hwu P, Hanmod SS, Jiang Y, Hachem RY, Raad II. The efficacy of catheters coated with minocycline and rifampin in the prevention of catheter-related bacteremia in cancer patients receiving high-dose interleukin-2. Int J Infect Dis 14(7):e548-52, 7/2010. e-Pub 12/14/2009. PMID: 20005762.
72. Williams MD, Esmaeli B, Soheili A, Simantov R, Gombos DS, Bedikian AY, Hwu P. GPNMB expression in uveal melanoma: a potential for targeted therapy. Melanoma Res 20(2):184-90, 6/2010. PMID: 20375921.
73. Liu S, Etto T, Rodríguez-Cruz T, Li Y, Wu C, Fulbright OJ, Hwu P, Radvanyi L, Lizée G. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy. J Immunother 33(4):371-81, 5/2010. PMID: 20386469.
74. Yoon C, Papadopoulos NE, Camacho LH, McIntyre S, Alvarado GC, Bedikian AY, Hwu P, Kim KB. The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. Melanoma Res 20(1):43-7, 2/2010. e-Pub 12/2009. PMID: 19952963.
75. Li Y, Liu S, Hernandez J, Vence L, Hwu P, Radvanyi L. MART-1-Specific Melanoma Tumor-Infiltrating Lymphocytes Maintaining CD28 Expression Have Improved Survival and Expansion Capability Following Antigenic Restimulation In Vitro. J Immunol 184(1):452-65, 1/1/2010. e-Pub 11/30/2009. PMID: 19949105.
76. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31(5):787-98, 11/20/2009. e-Pub 10/29/2009. PMCID: PMC2787786.
77. Montero AJ, Diaz-Montero CM, Millikan RE, Liu J, Do KA, Hodges S, Jonasch E, McIntyre BW, Hwu P, Tannir N. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-{alpha}: association of pretreatment serum levels with survival. Ann Oncol 20(10):1682-7, 10/2009. e-Pub 6/18/2009. PMID: 19541791.
78. Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma. Am J Clin Oncol 32(6):509-14, 10/2009. e-Pub 6/2009. PMID: 19506454.
79. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest 27(7):756-63, 8/2009. e-Pub 5/2009. PMID: 19440934.
80. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8(8)(8):2079-85, 8/2009. e-Pub 8/11/2009. PMCID: PMC3346953.
81. Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL, Hwu P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res 19(4):238-42, 8/2009. PMID: 19521262.
82. Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, Frasca L, Lou Y, Liu C, Andersson HA, Hwu P, Overwijk WW. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol 182(12):7398-7407, 6/15/2009. PMCID: PMC2774140.
83. Kim KB, Hwu WJ, Papadopoulos NE, Bedikian AY, Camacho LH, Ng C, Hernandez IM, Frost AM, Jack MA, Hwu P. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemother Pharmacol 64(1):161-7, 6/2009. e-Pub 11/11/2008. PMID: 19002462.
84. Thapa P, Zhang G, Xia C, Gelbard A, Overwijk WW, Liu C, Hwu P, Chang DZ, Courtney A, Sastry JK, Wang PG, Li C, Zhou D. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine 27(25-25):3484-8, 5/26/2009. e-Pub 2/5/2009. PMID: 19200815.
85. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 19(1):42-9, 2/2009. PMID: 19430405.
86. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 7(1):20-3, 1/2009. PMID: 19213663.
87. Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, Ballo MT, Myers JN, Hwu P, Kim KB. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 30(12):1592-8, 12/2008. e-Pub 12/2008. PMID: 18798304.
88. Quintás-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 5(12):737-40, 12/2008. e-Pub 10/21/2008. PMID: 18936790.
89. Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW, Cooper LJ, Gelovani J, Hwu P. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A 105(38):14342-6, 9/23/2008. e-Pub 9/15/2008. PMCID: PMC2567214.
90. Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Res 18(4):241-5, 8/2008. PMID: 18626307.
91. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, McIntyre S, Hwu P. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 26(6):624-33, 7/2008. e-Pub 7/2008. PMID: 18584354.
92. Bedikian AY, Johnson MM, Warneke CL, McIntyre S, Papadopoulos N, Hwu WJ, Kim K, Hwu P. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol 5(2)(2):201-7, 4/2008. PMID: 18569391.
93. Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 118(3)(3):1165-75, 3/2008. PMCID: PMC2230660.
94. Lee ST, Liu S, Radvanyi L, Sukhumalchandra P, Molldrem JJ, Wieder ED, Hwu P, Liu YJ, Kwak LW, Lizée G, Neelapu SS. A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. J Immunol Methods 331 (1-2)(1-2):13-26, 2/29/2008. e-Pub 10/9/2007. PMCID: PMC2265521.
95. Zhu K, Qin H, Cha SC, Neelapu SS, Overwijk W, Lizee GA, Abbruzzese JL, Hwu P, Radvanyi L, Kwak LW, Chang DZ. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine 25(46)(46):7955-61, 11/14/2007. e-Pub 9/14/2007. PMID: 17933439.
96. Liu S, Lizée G, Lou Y, Liu C, Overwijk WW, Wang G, Hwu P. IL-21 synergizes with IL-7 to augment expansion and antitumor function of cytotoxic T cells. Int Immunol 19(10)(10):1213-21, 10/2007. PMID: 17898044.
97. Zhu K, Lizee G, Cano P, Fernando-Vina M, Ji B, Abbruzzese JL, Hwu P, Radvanyi L, Chang DZ. HLA-A0201 positive pancreatic cell lines: new findings and discrepancies. Cancer Immunol Immunother 56(5):719-24, 5/2007. e-Pub 9/1/2006. PMID: 16947023.
98. Murphy A, Westwood JA, Brown LE, Teng MW, Moeller M, Xu Y, Smyth MJ, Hwu P, Darcy PK, Kershaw MH. Antitumor activity of dual-specific T cells and influenza virus. Cancer Gene Ther 14:499-508, 3/2007. PMID: 17332777.
99. Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, Wang G. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses (author Wang and Hwu equal contribution). J Immunol 178(3):1534-41, 2/1/2007. PMID: 17237402.
100. Leslie MC, Zhao YJ, Lachman LB, Hwu P, Wu GJ, Bar-Eli M. Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis. Gene Ther 14(4):316-23, 2/2007. e-Pub 10/5/2006. PMID: 17024104.
101. Lotem M, Zhao Y, Riley J, Hwu P, Morgan RA, Rosenberg SA, Parkhurst MR. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. J Immunother 29(6):616-27, Nov-Dec, 11/2006. PMCID: PMC2174598.
102. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12(20 Pt 1):6106-15, 10/15/2006. PMCID: PMC2154351.
103. Grover A, Kim GJ, Lizée G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST, Hwu P. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 12(19):5801-8, 10/1/2006. PMCID: PMC2174601.
104. Ozaki K, Hishiya A, Hatanaka K, Nakajima H, Wang G, Hwu P, Kitamura T, Ozawa K, Leonard WJ, Nosaka T. Overexpression of interleukin 21 induces expansion of hematopoietic progenitor cells. Int J Hematol 84(3):224-30, 10/2006. PMID: 17050196.
105. Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L. Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res 1;12(7 Pt 2):2291s-96s, 4/1/2006. PMID: 16609047.
106. Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, Hwu P, Zagars GK. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 64(1):106-13, 1/1/2006. e-Pub 9/22/2005. PMID: 16182463.
107. Ballo MT, Zagars GK, Gershenwald JE, Lee JE, Mansfield PF, Kim KB, Camacho LH, Hwu P, Ross MI. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol 11(12):1079-84, 12/2004. PMID: 15576833.
108. Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, Qi CF, Hwu P, Shaffer DJ, Akilesh S, Roopenian DC, Morse HC, Lipsky PE, Leonard WJ. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 1;173(9):5361-71, 11/1/2004. PMID: 15494482.
109. Lou Y, Wang G, Lizée G, Kim GJ, Finkelstein SE, Feng C, Restifo NP, Hwu P. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res 64(18):6783-90, 9/15/2004. PMCID: PMC2241750.
110. Wang G, Tschoi M, Spolski R, Lou Y, Ozaki K, Feng C, Kim G, Leonard WJ, Hwu P. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 63(24):9016-22, 12/15/2003. PMID: 14695220.
111. Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother 26(5):385-93, Sep-Oct, 9/2003. PMCID: PMC1764125.
112. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21(16):3127-32, 8/15/2003. PMCID: PMC2275327.
113. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 9(8):2973-80, 8/1/2003. PMCID: PMC2259234.
114. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427-34, 7/31/2003. PMCID: PMC2275324.
115. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100(14):8372-7, 7/8/2003. e-Pub 6/25/2003. PMCID: PMC166236.
116. Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 26(4):349-56, Jul-Aug, 7/2003. PMCID: PMC1679660.
117. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 63(11):2836-43, 6/1/2003. PMID: 12782589.
118. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 14(8):709-14, 5/20/2003. PMCID: PMC2078240.
119. O'Reilly F, Feldman E, Yang J, Hwu P, Turner ML. Recurring cutaneous eruption in a patient with metastatic renal cell carcinoma being treated with high-dose interleukin 2. J Am Acad Dermatol 48(4):602-4, 4/2003. PMID: 12664026.
120. Kershaw MH, Westwood JA, Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 20(12):1221-7, 12/2002. e-Pub 11/4/2002. PMID: 12415288.
121. Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, Wang E, Young HA, Murphy PM, Hwu P. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 13(16):1971-80, 11/1/2002. PMID: 12427307.
122. Sloan JM, Kershaw MH, Touloukian CE, Lapointe R, Robbins PF, Restifo NP, Hwu P. MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells. Cancer Gene Ther 9(11):946-50, 11/2002. PMCID: PMC1764124.
123. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594):850-4, 10/25/2002. e-Pub 9/19/2002. PMCID: PMC1764179.
124. Touloukian CE, Leitner WW, Robbins PF, Li YF, Kang X, Lapointe R, Hwu P, Rosenberg SA, Restifo NP. Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Cancer Res 62(18):5144-7, 9/15/2002. PMCID: PMC2248802.
125. Royal RE, Kershaw MH, Reeves ME, Wang G, Daly T, Treisman J, Lam J, Hwu P. Increased functional expression of transgene in primary human lymphocytes using retroviral vectors modified with IRES and splicing motifs. Gene Ther 9(16):1085-92, 8/2002. PMID: 12140736.
126. Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC, Restifo NP, Hwu P, Wang RF. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells for generation of potent antitumor immunity. J Clin Invest 109(11):1463-70, 6/2002. PMCID: PMC151000.
127. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25(3):243-51, May-Jun, 5/2002. PMCID: PMC2413438.
128. Marroquin CE, Westwood JA, Lapointe R, Mixon A, Wunderlich JR, Caron D, Rosenberg SA, Hwu P. Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J Immunother 25(3):278-88, May-Jun, 5/2002. PMCID: PMC2553208.
129. Hwu P, Freedman RS. The immunotherapy of patients with ovarian cancer. J Immunother 25(3):189-201, May-Jun, 5/2002. PMID: 12000860.
130. Toso JF, Lapointe R, Hwu P. CD40 ligand and lipopolysaccharide enhance the in vitro generation of melanoma-reactive T-cells. J Immunol Methods 259(1-2):181-90, 1/1/2002. PMID: 11730853.
131. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20(1):142-52, 1/1/2002. PMCID: PMC2064865.
132. Kershaw MH, Hsu C, Mondesire W, Parker LL, Wang G, Overwijk WW, Lapointe R, Yang JC, Wang RF, Restifo NP, Hwu P. Immunization against endogenous retroviral tumor-associated antigens. Cancer Res 61(21):7920-4, 11/2001. PMID: 11691813.
133. Lapointe R, Royal RE, Reeves ME, Altomare I, Robbins PF, Hwu P. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. J Immunology 167:4758-64, 10/2001. PMID: 11591807.
134. Moir S, Malaspina A, Ogwaro KM, Donoghue ET, Hallahan CW, Ehler LA, Liu S, Adelsberger J, Lapointe R, Hwu P, Baseler M, Orenstein JM, Chun TW, Mican JA, Fauci AS. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A 98(18):10362-7, 8/2001. PMID: 11504927.
135. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24:363-73, 7/2001. PMID: 11565838.
136. Kershaw MH, Westwood JA, Zhu Z, Witte L, Libutti SK, Hwu P. Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature. Hum Gene Ther 11(18):2445-52, 12/2000. PMID: 11119416.
137. Parker LL, Do MT, Westwood JA, Wunderlich JR, Dudley ME, Rosenberg SA, Hwu P. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 11(17):2377-87, 11/2000. PMID: 11096442.
138. Lapointe R, Toso JF, Butts C, Young HA, Hwu P. Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes. Eur J Immunol 30(11):3291-8, 11/2000. PMID: 11093145.
139. Chinnasamy N, Chinnasamy D, Toso JF, Lapointe R, Candotti F, Morgan RA, Hwu P. Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors. Hum Gene Ther 11(13):1901-9, 9/2000. PMID: 10986562.
140. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164(7):3596-9, 4/2000. PMID: 10725715.
141. Feldman AL, Restifo NP, Alexander HR, Bartlett DL, Hwu P, Seth P, Libutti SK. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 60(6):1503-6, 3/2000. PMID: 10749112.
142. Daly T, Royal RE, Kershaw MH, Treisman J, Wang G, Li W, Herlyn D, Eshhar Z, Hwu P. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. Cancer Gene Ther 7(2):284-91, 2/2000. PMID: 10770638.
143. Moir S, Lapointe R, Malaspina A, Ostrowski M, Cole CE, Chun TW, Adelsberger J, Baseler M, Hwu P, Fauci AS. CD40-mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir. J Virol 73:7972-80, 10/1999. PMID: 10482544.
144. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Sznol M, Schwarz SL, Spiess PJ, Wunderlich JR, Seipp CA, Einhorn JH, Rogers-Freezer L, White DE. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 163:1690-5, 8/1999. PMID: 10415076.
145. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 163:507-13, 7/1999. PMID: 10384155.
146. Pack SD, Karkera JD, Zhuang Z, Pak ED, Balan KV, Hwu P, Park WS, Pham T, Ault DO, Glaser M, Liotta L, Detera-Wadleigh SD, Wadleigh RG. Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations. Genes Chromosomes Cancer 25:160-8, 6/1999. PMID: 10338000.
147. Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, Restifo NP. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 162:5728-37, 5/1999. PMID: 10229805.
148. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17:968-75, 3/1999. PMID: 10071291.
149. Wu PC, Alexander HR, Huang J, Hwu P, Gnant M, Berger AC, Turner E, Wilson O, Libutti SK. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res 59(1):205-12, 1/1/1999. PMID: 9892208.
150. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90(24):1894-900, 12/16/1998. PMCID: PMC2249697.
151. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4(3):321-7, 3/1998. PMCID: PMC2064864.
152. Wang G, Chopra RK, Royal RE, Yang JC, Rosenberg SA, Hwu P. A T-cell independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nat Med 4(2):168-72, 2/1998. PMID: 9461189.
153. Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, Hwu P. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 186(8):1213-21, 10/20/1997. PMCID: PMC2199086.
154. Reeves ME, Royal RE, Lam JS, Rosenberg SA, Hwu P. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 56(24):5672-7, 12/15/1996. PMID: 8971174.
155. Lam JS, Reeves ME, Cowherd R, Rosenberg SA, Hwu P. Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope. Hum Gene Ther 7(12):1415-22, 8/1/1996. PMID: 8844200.
156. Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res 56(12):2832-6, 6/15/1996. PMCID: PMC2248455.
157. Royal RE, Steinberg SM, Krouse RS, Heywood G, White DE, Hwu P, Marincola FM, Parkinson DR, Schwartzentruber DJ, Topalian SL, Yang JC, Rosenberg SA. Correlates of response to IL2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am 2(2):91-8, Mar-Apr, 3/1996. PMID: 9166506.
158. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55(15):3369-73, 8/1/1995. PMID: 7614473.
159. Treisman J, Hwu P, Minamoto S, Shafer GE, Cowherd R, Morgan RA, Rosenberg SA. Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 85(1):139-45, 1/1/1995. PMID: 7803791.
160. Treisman J, Hwu P, Yannelli JR, Shafer GE, Cowherd R, Samid D, Rosenberg SA. Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid. Cell Immunol 156(2):448-57, 7/1994. PMID: 8025957.
161. Rosenberg SA, Anderson WF, Blaese M, Hwu P, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Ettinghausen SE. The development of gene therapy for the treatment of cancer. Ann Surg 218(4):455-63; discussion 463-4, 10/1993. PMCID: PMC1242999.
162. Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R, Rosenberg SA, Eshhar Z. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 178(1):361-6, 7/1/1993. PMCID: PMC2191075.
163. Yannelli JR, Hyatt C, Johnson S, Hwu P, Rosenberg SA. Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor alpha (TNF-a) or interleukin-2 (IL-2). J Immunol Methods 161(1):77-90, 5/5/1993. PMID: 8486931.
164. Hwu P, Yannelli J, Kriegler M, Anderson WF, Perez C, Chiang Y, Schwarz S, Cowherd R, Delgado C, Mulé J. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans. J Immunol 150(9):4104-15, 5/1/1993. PMID: 8473752.
165. Karp SE, Farber A, Salo JC, Hwu P, Jaffe G, Asher AL, Shiloni E, Restifo NP, Mulé JJ, Rosenberg SA. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor. J Immunol 150(3):896-908 acted as mentor, 2/1/1993. PMCID: PMC2121323.
166. Karp SE, Hwu P, Farber A, Restifo NP, Kriegler M, Mulé JJ, Rosenberg SA. In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor. J Immunol 149(6):2076-81, 9/15/1992. PMCID: PMC2121327.
167. Hwu P, Schwarz S, Custer M, Smith CA, Mulé JJ, Rosenberg SA. Use of soluble recombinant TNF receptor to improve detection of TNF secretion in cultures of tumor infiltrating lymphocytes. J Immunol Methods 151(1-2):139-47, 7/6/1992. PMID: 1321199.
168. Young HA, Varesio L, Hwu P. Posttranscriptional control of human gamma interferon gene expression in transfected mouse fibroblasts. Mol Cell Biol 6(6):2253-6, 6/1986. PMCID: PMC367767.

Invited Articles

1. Weber JS, Atkins MB, Hwu P, Radvanyi L, Sznol M, Yee C. White Paper on Adoptive Cell Therapy for Cancer with Tumor Infiltrating Lymphocytes: a report of the CTEP Subcommittee on Adoptive Cell Therapy. Clin Cancer Res 29(18):3476-82, 4/2011. e-Pub 2/2011. PMID: 21325070.
2. Balwit JM, Hwu P, Urba WJ, Marincola FM. The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program. J Transl Med 9:18, 1/2011. PMID: 21281484.
3. Balwit JM, Hwu P, Urba WJ, Marincola FM. The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program. J Transl Med 9(1):18, 1/2011. e-Pub 1/2011. PMID: 21281484.
4. Li Y, Liu S, Margolin K, Hwu P. Summary of the primer on tumor immunology and the biological therapy of cancer. J Transl Med 7(11):11, 2009. e-Pub 1/28/2009. PMCID: PMC2645355.
5. Lizée G, Cantu MA, Hwu P. Confronting the barriers to cancer immunotherapy. Clin Cancer Res 13(18)(18 Pt 1):5250-55, 9/15/2007. e-Pub 9/2007. PMID: 17875752.
6. Carson WE, Allen A, Weiner LM, Cheever MA, Fox BA, Keilholz U, Wigginton JM, Sondel PM, Atkins MB, Hwu P. Immunotherapy comes of age: overview of the 21(st) Annual Meeting and associated programs of the International Society for Biological Therapy of Cancer Los Angeles, CA, USA, 27 - 29 October 2006. Expert Opin Biol Ther 7:419-422, 3/2007. PMID: 17309333.
7. Lizée G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 15;12(16):4794-803, 8/15/2006. PMID: 16914564.
8. Lizée G, Radvanyi LG, Overwijk WW, Hwu P. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin Cancer Res 12(7 Pt 2):2359s-65s, 4/1/2006. PMID: 16609059.
9. Hwu P. Current challenges in cancer gene therapy. J Intern Med Suppl 242 (supplement 740):109-14, 1997. PMID: 9350191.
10. Hwu P. The Gene Therapy of Cancer. Principles and Practice of Oncology Update Series 9:1-13, 1995.
11. Hwu P, Rosenberg SA. The use of gene-modified tumor-infiltrating lymphocytes for cancer therapy. Ann N Y Acad Sci 716:188-97; discussion 197-203, 5/31/1994. PMID: 8024194.
12. Hwu P, Rosenberg SA. The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials. Cancer Detect Prev 18(1):43-50, 1994. PMID: 8162605.
13. Hwu P. What the Future Holds for Gene Therapy. Internal Medicine 15:39, 1994.


1. Hwu P. Treating cancer by targeting the immune system. N Engl J Med 363(8):779-81, 8/19/2010. PMID: 20818880.
2. Hwu P, Bedikian AY, Grimm EA. Challenges of chemosensitivity testing. Clin Cancer Res 12(18):5258-9, 9/15/2006. PMID: 17000655.

Book Chapters

1. Gershenwald J, Hwu P. Section 31, Chapter 105: Melanoma. In: Holland - Frei Cancer Medicine, 8th. Ed(s) Hong, Bast, Hait, Kufe, Pollock, Weichselbaum, Holland, Frei. People's Medical Publishing House-USA: Shelton, CT, 1459-86, 2010. ISBN: 1-60795-014-6.
2. Lui YG, Hwu P. Cancer and the Cellular Immune Response. In: The Molecular Basis of Cancer, 3rd. Ed(s) Mendelsohn, Howley, Isreal, Gray, Thompson. Saunders Elsevier: Philadelphia, 635-47, 2008.
3. Hwu P. The Gene Therapy of Cancer. In: Cancer: Principles and Practice of Oncology, 7th. J.B. Lippincott: Philadelphia, 2819-38, 2005.
4. Hwu P. Newer Approaches in Cancer Treatment: Genetic Therapy. In: Cancer: Principles and Practice on Oncology, 6th. Lippincott: Philadelphia, 3161-80, 2001.
5. Hwu P. The Genetic Modification of Lymphocytes for Cancer Immunotherapy. In: Biologic Therapy of Cancer, 3rd. Ed(s) DeVita, Hellman, Rosenberg. J.B. Lippincott: Philadelphia, 757-69, 2000.
6. Hwu P, Rosenberg S. The Gene Therapy of Cancer. In: Cancer: Principles and Practice of Oncology, 5th. J.B. Lippincott: Philadelphia, 3005-22, 1996.
7. Hwu P, Rosenberg SA. The Genetic Modification of Lymphocytes for Cancer Immunotherapy. In: Biologic Therapy of Cancer, 2nd. Ed(s) DeVita, Hellman, Rosenberg. J.B. Lippincott: Philadelphia, 727-37, 1995.

Letters to the Editor

1. Radvanyi L, Pilon-Thomas S, Peng W, Sarnaik A, Mulé JJ, Weber J, Hwu P. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter. Clin Cancer Res 19(19):5541, 10/1/2013. e-Pub 9/18/2013. PMCID: PMC3823378.

Manuals, Teaching Aids, Other Teaching Publications

1. Schorr, Andrew. Interview of Dr. Patrick Hwu for Patient Power Webcast Advances in the Treatment of Melanoma: Houston, Texas, http//, 5/2008.
2. Housemann, Sunni. Oncolog Cover Story. New Approaches for Advanced Melanoma feature the work of Dr. Patrick Hwu, Dr. Elizabeth Grimm, Dr. Jeffrey Gershenwald, Dr. Victor Prieto, Dr. Kevin Kim and others. 52:3. Ed(s) M Fisch, L Green, T Beavers, E Estey, R Gagel, B Handy, P Hwu, M Markman, S Patel, D Schwartz, R Sellin, R Weber, C Wood. M. D. Anderson Cancer Center: Houston, Texas, 1-4, 3/2007.
3. Watson, Sarah. Promise Cover Story. Protection from Within: Using the Body's Immune System to Fight Cancer. This story features Dr. Patrick Hwu's patient Elaine Silk as well as Research Nurse Priscilla Miller. Promise Newsletter is published quarterly by the Development Office at The University of Texas M. D. Anderson Cancer Center in Houston and distributed to friends of the institution as well as potential supporters, and is available on-line and in print. Ed(s) DeDe Destefano: Houston, Texas,, 11/2006.
4. DoCMessages A Division of Cancer Medicine Information Exchange. Immunotherapy Research Expands: A Conversation with New Melanoma Chair, Dr. Patrick Hwu. DoCMessage is a quarterly publication for faculty and staff of The University of Texas, M. D. Anderson Cancer Center, Division of Cancer Medicine: Houston, Texas, e-Pub 9/2006.
5. Poirot, Carolyn. A shot against cancer: Using vaccines, researchers are working to turn patients' bodies into cancer-fighting machines -- and ushering in a new season of hope. This article features Dr. Patrick Hwu and other researchers of cancer vaccines. May 28, 2006. Fort Worth, Texas Star Telegram: Fort Worth, Texas, 5/2006.
6. Hwu P. OncoLog Report to Physicians Dialog, Cancer Vaccines and Immunotherapy. Report to physicians about cancer and research. Available online at 51:5, May 2006. M. D. Anderson Cancer Center: Houston, Texas,, 5/2006.
7. Watson, Sarah. Promise. From bench to breakthrough. Winter. Ed(s) DeDe DeStefano. M. D. Anderson Cancer Center: Houston, Texas, USA, 2, 2006.
8. Hwu P, Mills J. Melanoma Medical Oncology e-newsletter was launched by e-mail in December 2005. This bi-annual newsletter from M. D. Anderson cancer Center, Department of Melanoma Medical Oncology is meant to update referring physicians about the latest advances at our facility, and is available online and in print. M.D. Anderson Cancer Center: Houston, Texas, 12/2005.
9. Hwu P, Mills J. The University of Texas, M. D. Anderson Cancer Center, Department of Melanoma Medical Oncology Website launched to the web in November of 2005 M. D. Anderson Cancer Center: Houston, Texas,, 11/2005.
10. Ellig, E. Conquest Magazine, Cover Story and Featured Articles regarding the faculty of The University of Texas, M. D. Anderson Cancer Center, Department of Melanoma Medical Oncology, Melanoma Comes Under Attack. 20:1, Summer 2005. M. D. Anderson Cancer Center: Houston, Texas, http:/, 8/2005.
11. Cover Story for the South Campus Research Initiative fund raising brochure for the Red and Charline McCombs Institute for Early Detection and Treatment of Cancer, Pt Ms. Gail Robert and Dr. Patrick Hwu. Summer 2005. The University of Texas, M. D. Anderson Cancer Center: Houston, Texas, 8/2005.
12. Ellig, E. The University of Texas, M. D. Anderson Cancer Center, Department of Melanoma Medical Oncology, Philanthropic Departmental Brochure, Target Melanoma: Melanoma Medical Oncology team takes on malignant skin cancer, Requested with input by Dr. Patrick Hwu. designed by Kelley Moore, produced by MDACC Publications and Creative Services 2005: Houston, Texas, 8/2005.

Grant & Contract Support

Title: The Role of the PI3K Pathway in Immune Resistance
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 7/1/2014 - 6/30/2019

Last updated: 7/9/2014